Stay updated with breaking news from Carl Danzig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Last week's FDA approval of avacincaptad pegol marked the second approved treatment for geographic atrophy in 2023. Here, 4 retina specialists discuss the complement inhibitor and what it could represent for patients with GA.
A relationship was found between geographic atrophy growth and worsening vision loss in a post hoc analysis of the phase 3 GATHER1 and GATHER2 pivotal clinical trials investigating avacincaptad pegol, according to Iveric Bio.
In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.
- Post-hoc analysis from the GATHER trials, for the first time, signals that reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced geographic atrophy ... | April 23, 2023